Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multicenter, Open-Label, Dose-Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered JBI-778 in Patients With Brain Metastasis, Leptomeningeal Disease, or High Grade Recurrent Glioma

NCT07751744 is registered in ClinicalTrials.gov with Jubilant Therapeutics Inc. as lead sponsor.

NCT NCT07751744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07751744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered JBI-778 in Patients With Brain Metastasis, Leptomeningeal Disease, or High Grade Recurrent Glioma
Lead sponsor
Jubilant Therapeutics Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 1, 2028
Completion date
March 31, 2030
Enrollment
113 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases from solid tumors, glioblastoma (gbm), high grade glioma (hgg), leptomeningeal disease